Schizophrenia News From Medical News Today Latest Health News and Medical News posted throughout the day, every day.
Naltrexone Nixed For Substance Abuse In Patients With Schizophrenia
Munich, Germany - Contrary to expectations, the opioid receptor antagonist naltrexone is no better than placebo and can be counterproductive in treating substance use disorder in patients with schizophrenia, according to data released at the 18th European Congress of Psychiatry...
Schizophrenia Gene Network Analysis Identifies Age-Associated Defects
The underlying causes of the debilitating psychiatric disorder schizophrenia remain poorly understood. In a study published online in Genome Research, scientists have performed a powerful gene network analysis that has revealed surprising new insights into how gene regulation and age play a role in schizophrenia...
Prolonged Cannabis Use Linked To Psychosis
An Australian study found that prolonged use of cannabis or marijuana by young adults was linked to a higher risk of developing psychosis, with the highest risk affecting those who started using the substance in their teens, and continued using it for 6 years or more into adulthood: the risk of developing psychosis among these users was more than double that of never users...
Why Symptoms Of Schizophrenia Emerge In Young Adulthood
In reports of two new studies, researchers led by Johns Hopkins say they have identified the mechanisms rooted in two anatomical brain abnormalities that may explain the onset of schizophrenia and the reason symptoms don't develop until young adulthood...
Possible Insight Into The Schizophrenic Brain Via Mouse Model
Schizophrenia is an incredibly complex and profoundly debilitating disorder that typically manifests in early adulthood but is thought to arise, at least in part, from pathological disturbances occurring during very early brain development...
Autism And Schizophrenia: Research Builds On Genetic Link
A genetic link between schizophrenia and autism is enabling researchers to study the effectiveness of drugs used to treat both illnesses. Dr Steve Clapcote from the University of Leeds's Faculty of Biological Sciences will be analysing behaviour displayed by mice with a genetic mutation linked to schizophrenia and autism and seeing how antipsychotic drugs affect their behavioural abnormalities...
"Brain Bank" To Foster Research, Treatment Of Major Psychiatric Diseases
Johns Hopkins Children's Center neurovirologist Robert Yolken, M.D., and collaborators from the Stanley Medical Research Institute have developed a large repository of brain and tissue samples to advance the understanding and treatment of bipolar disorder, major depression and schizophrenia...
Alkermes Unveils Long-Acting Injectable Proprietary Platform For Treatment Of Schizophrenia And Other CNS Disorders
Alkermes, Inc. (NASDAQ: ALKS) announced that it has developed a novel, proprietary LinkeRxв„ў technology platform to enable the creation of injectable extended-release versions of antipsychotics and other central nervous system (CNS) therapies...
Merz Pharma Announces Launch Of Denzapine As First Available Generic For Treatment-Resistant Schizophrenia
Today Merz Pharma entered the Irish Healthcare market with Denzapine, the first generic form of clozapine available in Ireland. Denzapine is an atypical antipsychotic agent used in treatment-resistant schizophrenia (TRS) which has been available to prescribe in the UK since February 2004...
In Schizophrenia And Bipolar Disorder, Life Is Not Black And White
Schizophrenia and bipolar disorder affect tens of millions of individuals around the world. These disorders have a typical onset in the early twenties and in most cases have a chronic or recurring course. Neither disorder has an objective biological marker than can be used to make diagnoses or to guide treatment...
Fish Oil May Reduced Risk Of Psychotic Disorders In High Risk Individuals
A new study suggests that people at very high risk of developing psychotic disorders appear less likely to to do so after taking fish oil for three months...
The Prevention Of Psychiatric Patient Suicides
Between 1997 and 2006, 38% of out-of-clinic suicides by mental health patients were carried out by people absent without leave from the hospital. Researchers writing in the open access journal BMC Psychiatry suggest that measures to improve the ward environment or prevent patients from leaving psychiatric wards without staff agreement could avoid up to 50 suicide deaths every year...
Identification Of Brain Protein For Synapse Development
A new study from UC Davis Health System identifies for the first time a brain protein called SynDIG1 that plays a critical role in creating and sustaining synapses, the complex chemical signaling system responsible for communication between neurons. The research, published in the Jan...
Early Intervention Could Prevent Schizophrenia
The onset of schizophrenia is not easy to predict. Although it is associated with as many as 14 genes in the human genome, the prior presence of schizophrenia in the family is not enough to determine whether one will succumb to the mind-altering condition. The disease also has a significant environmental link. According to Prof...
Duke To Lead Effort To Better Understand The Role Of Rare Genetic Variation In Clozapine-induced Agranulocytosis Using Whole Genome Sequencing
The International Serious Adverse Events Consortium (SAEC) has announced that it will collaborate with Duke University's Center for Human Genome Variation to research the genetics of Clozapine-induced agranulocytosis (CIA), with the goal of identifying potential rare genetic variants predictive of this serious drug induced adverse event...
The Hidden Cost Of Schizophrenia
People being treated for schizophrenia are more likely than the general population to have encounters with the criminal justice system in the US...
Childhood Clues To Adult Schizophrenia
Years before adults develop schizophrenia, there is a pattern of cognitive difficulties they experience as children, including problems with verbal reasoning, working memory, attention and processing speed...
Blood Test For Schizophrenia Could Be Ready This Year
A blood test for diagnosing schizophrenia - the most serious form of mental illness - could be available this year, according to an article in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine. The disorder, with symptoms that can include hallucinations and delusional thoughts, affects more than two million people in the United States and millions more worldwide...
Launch Of Largest Academic-Industry Collaboration For Drug Discovery In Depression And Schizophrenia
An international consortium of scientists, led by H. Lundbeck A/S and King's College London, has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for schizophrenia and depression...
A Flying Boost For Neuroscience
Understanding the causes of autism and schizophrenia could be a step closer for researchers from the Queensland Brain Institute at The University of Queensland after they unravelled the secret world of the wasp genome. The neuroscientists were part of an international consortium that has spent four years sequencing the genome of three parasitic wasp species...
Examining The Impact Of FDA Safety Warnings
A study published in the Archives of Internal Medicine examines the impact of a safety warning issued by the Food and Drug Administration for commonly prescribed antipsychotic medications...
Race-Based Misdiagnosis Still Remains A Health Care Problem
Black men are over-diagnosed with schizophrenia at least five times higher than any other group - a trend that dates back to the 1960s, according to new University of Michigan research...
Dainippon Sumitomo Pharma America Announces The NDA Submission Of Lurasidone To The FDA For The Treatment Of Schizophrenia
Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lurasidone, an investigational atypical antipsychotic agent for the treatment of schizophrenia...
EnVivo Enters Phase 2b Trials For Its EVP-6124 Compound In The Treatment Of Schizophrenia
EnVivo Pharmaceuticals announced the initiation and dosing of patients in a Phase 2b study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with schizophrenia. EnVivo is conducting the multi-center, dose ranging, placebo controlled, three-month study in the U.S. and Europe...
Before Or After Birth, Gene Linked To Mental Health Has Different Effects
Scientists have long eyed mutations in a gene known as DISC1 as a possible contributor to schizophrenia and mood disorders, including depression and bipolar disorder...
Worlds Best Pharmacy
canadian meds shop
Why is your product so cheap? How do you ship orders? We accept : Visa, MasterCard, AmEx, Diners and JCB cards. |
